ストックスクリーナーアプリを入手
42.69
3.13%
1.1837
前日終値:
$41.51
開ける：
$41.69
24時間の取引高:
142.64K
Relative Volume:
0.41
時価総額：
$2.96B
収益：
$751.00K
当期純損益:
$-74.57M
株価収益率:
-38.70
EPS:
-1.1031
ネットキャッシュフロー:
$-55.52M
1週間 パフォーマンス:
+12.16%
1か月 パフォーマンス:
+62.84%
6か月 パフォーマンス:
+69.54%
1年 パフォーマンス:
+187.70%
1日の値動き範囲:
$41.00
$43.52
1週間の範囲:
$36.58
$45.90
52週間の値動き範囲:
$12.56
$45.90
Pulse Biosciences Inc Stock (PLSE) Company Profile
Compare PLSE vs ISRG, BDX, ALC, RMD, MDLN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
42.76 | 2.27B | 751.00K | -74.57M | -55.52M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
398.68 | 127.84B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
179.35 | 43.79B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
75.22 | 32.81B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
220.88 | 29.46B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
33.96 | 33.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | 開始されました | Mizuho | Outperform |
| 2025-07-07 | 開始されました | Oppenheimer | Outperform |
| 2021-07-27 | 開始されました | Stephens | Overweight |
| 2021-03-11 | 開始されました | Maxim Group | Buy |
| 2021-01-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-12 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Pulse Biosciences Inc (PLSE) 最新ニュース
Oppenheimer Adjusts Pulse Biosciences PT to $35 From $30, Maintains Outperform Rating - marketscreener.com
Oppenheimer raises Pulse Biosciences stock price target on AF data - Investing.com
Pulse Biosciences Inc (PLSE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulse Biosciences Inc (PLSE) Cash Flow - TradingKey
PLSE|Pulse Biosciences Inc|Price:30.230|Chg%:-0.770 - TradingKey
TradingKey - TradingKey
Pulse Biosciences, Inc Revenue Breakdown – NASDAQ:PLSE - TradingView
This Little-Known Biotech Stock Just Hit a New 5-Year High - Yahoo Finance
Pulse Biosciences Inc (PLSE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pulse Biosciences stock hits 52-week high at 31.09 USD By Investing.com - Investing.com Australia
Pulse Biosciences stock hits 52-week high at 31.09 USD - Investing.com
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026 - Finviz
Pulse Biosciences to report Q2 2026 results on August 6 - scanx.trade
$Pulse Biosciences (PLSE.US)$ squeeze baby squeeze - Moomoo
Pulse Biosciences, Inc (PLSE) Stock Analysis: Unpacking The 5.89% Potential Upside - DirectorsTalk Interviews
PULSE BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) - Moomoo
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Liquidity Mapping Around (PLSE) Price Events - Stock Traders Daily
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - AOL.com
Pulse Biosciences stock stays tied to filings and financing - AD HOC NEWS
Why (PLSE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Did Warrant Redemptions Just Reframe Pulse Biosciences' (PLSE) Cardiac Ablation Investment Narrative? - Sahm
Price to earnings forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
PLSE Forecast — Price Target — Prediction for 2027 - TradingView
Pulse Biosciences Shares Tumble Over 5% as Bearish Momentum BuildsMonthly Profile - dars.gov.et
Price to sales forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Price to book forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Enterprise value to EBITDA forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Enterprise value to EBIT forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Price to book forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Enterprise value to revenue forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Enterprise value to revenue forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Price to sales forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Price to earnings forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Pulse Biosciences Inc (PLSE) Institutional Confidence - TradingKey
Pulse Biosciences stock hits 52-week high at $28.68 By Investing.com - Investing.com Nigeria
Pulse Biosciences stock hits 52-week high at $28.68 - Investing.com
Pulse Biosciences, Inc. Actuals & Estimates (NASDAQ:PLSE) - TradingView
Pulse Biosciences, Inc. Actuals & Estimates (FWB:6L8) - TradingView
Pulse Biosciences, Inc. Actuals & Estimates (DUS:6L8) - TradingView
6L8 Forecast — Price Target — Prediction for 2027 - TradingView
Pulse Biosciences Inc (PLSE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth - Moomoo
Pulse Biosciences Inc (PLSE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulse Biosciences (PLSE) Is Up 5.0% After Joining S&P Healthcare Equipment Index Is Sentiment Shifting? - simplywall.st
Pulse Biosciences, Inc.(NasdaqCM:PLSE) added to S&P Healthcare Equipment Select Industry Index - marketscreener.com
Understanding Momentum Shifts in (PLSE) - Stock Traders Daily
Pulse Biosciences Stockweekly review and sector comparison - AD HOC NEWS
Pulse Biosciences Inc (PLSE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulse Biosciences Strengthens Executive Team - Medical Product Outsourcing
Pulse Biosciences Inc (PLSE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pulse Biosciences Inc (PLSE) 財務データ
収益
当期純利益
現金流量
EPS
Pulse Biosciences Inc (PLSE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
0.40%
大文字化:
|
ボリューム (24 時間):